When Is the Broken Heart Most Dangerous? Assessing Risk Factors to Predict Inpatient Death in Takotsubo Cardiomyopathy: Analysis of the National Inpatient Sample for 2021

心碎何时最危险?评估预测心碎症住院患者死亡的风险因素:2021年全国住院样本分析

阅读:1

Abstract

BACKGROUND: Takotsubo cardiomyopathy (TC) has a similar clinical presentation to acute coronary syndromes (ACS). As the prevalence and influence on clinical decisions of this condition are being increasingly recognized, prognostic factors have yet to be established. We applied known near-term acute coronary syndrome mortality risk factors to determine their prognostic value in TC. This study aimed to assess the patient characteristics and comorbidities predicting inpatient death from TC. Understanding these risk factors is essential for clinical decision making and improving prognostic assessments. METHODS: We analyzed the National Inpatient Sample database for 2021. Inclusion criteria were principal diagnosis of TC (International Classification of Diseases, Tenth Revision [ICD-10] code I51.81) and age ≥18 years. Different comorbidities, age, and sex were analyzed, and the primary outcome was inpatient death. Univariate logistic regression was used to test the association of each factor with death, and multivariate logistic regression was then used to test for independent predictive value. RESULTS: A total of 9109 admissions for TC were identified (10.3% men and 89.7% women) with a mean age of 67 years and an inpatient mortality rate of 2.31%. On univariate regression, age (odds ratio [OR], 1.04; P=0.013), heart failure (OR, 3.2; P<0.001), atrial fibrillation (OR, 3.12; P<0.001), and chronic kidney disease (OR, 3.54; P<0.001) were significant predictors of inpatient death. On multivariate regression, only heart failure (OR, 2.8; P=0.007) and chronic kidney disease (OR, 2.34; P=0.032) were independently associated with inpatient death. CONCLUSIONS: Preexisting heart failure and a history of chronic kidney disease are poor prognostic factors in patients presenting with TC. Further large-scale studies are required to validate our findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。